Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study).

Trial Profile

Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Atenolol (Primary) ; Telmisartan (Primary)
  • Indications Aortic valve disorders
  • Focus Therapeutic Use
  • Acronyms BAV
  • Most Recent Events

    • 15 Aug 2016 Status changed from recruiting to completed.
    • 26 Nov 2012 Planned number of patients changed from 352 to 416 as reported by ClinicalTrials.gov.
    • 14 Jul 2011 Actual initiation date (June 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top